Awareness and Acceptance of Nicotine-free Smoking Intervention Methods (Acetium® Lozenge) Increased Among Health Care Professionals by Targeted E-training as Confirmed by Post-training Surveys.

BACKGROUND/AIM: To increase the awareness and acceptance of the new nicotine-free smoking intervention method (Acetium® lozenge; Biohit Oyj, Finland), targeted E-Training with accompanying surveys were conducted in 2018, 2020 and 2023. PATIENTS AND METHODS: The target groups were derived from the General Data Protection Regulation (GDPR)-compliant registers of Finnish physicians, pharmacy staff and nurses owned by Success Clinic Oy. The post-training surveys recorded 1) awareness of the responders on Acetium® lozenge, 2) their attitude to nicotine-free smoking intervention methods in general as well as 3) their readiness for recommending this new tool to their patients. RESULTS: The three surveys accumulated a total of 1.892 responders. There was a constantly increasing awareness on Acetium® lozenge, increased interest in nicotine-free smoking intervention methods in general and a substantially increased readiness to recommend Acetium® acceptance to the smoking patients. The impact of E-Training, as measured by the increased interest in nicotine-free methods (56%) and readiness to endorse Acetium® acceptance (58%), was most marked among nurses who had the least awareness on Acetium® lozenge beforehand, exceeding the respective increase among medical doctors by 20% and 10% and among pharmacy staff by 30% and 20%, respectively. CONCLUSION: This E-Training had a favorable effect 1) on the responders' interest in nicotine-free smoking intervention method in general, 2) on increasing the awareness of Acetium® lozenge as a novel innovative method to quit smoking, as well as 3) on increasing the responders' readiness to introduce the new device to their smoking patients who are motivated to stop smoking nicotine-free.

Impact of a physician-targeted letter on opioid prescribing.

We study the effect of a physician-targeted nudge letter on opioid prescribing. In May 2017, the Social Insurance Institution of Finland sent a personal information letter to all physicians who had issued a prescription containing at least 100 tablets of paracetamol-codeine combination to a new patient. The aim of the letter was to draw the physicians' attention to their prescribing practices and to decrease the size of the first codeine prescription. Using individual level register data and a difference-in-differences strategy, we estimate that the letter decreased the average number of tablets purchased by new patients by 12.5 percent and the probability of a first purchase being at least 100 tablets by six percentage points. We also find that these effects were larger among consistent high prescribers. However, we do not find similar effects on other mild or strong opioids.

Growth of diabetes drug expenditure decomposed-A nationwide analysis.

OBJECTIVES: The aim of this study was to quantify different factors underlying the growth of diabetes drug expenditure in Finland. METHODS: Data representing purchases of antidiabetic agents between 2003 and 2015 were extracted from a nationwide prescription register. By using Fisher's Ideal Indexes, the per capita expenditure growth for both insulins and non-insulin antidiabetic agents was decomposed into six different determinants: purchase volume, purchase size, switches between therapeutic classes, switches within therapeutic classes, unit costs and switches to generic alternatives. RESULTS: Between 2003 and 2015, the per capita expenditure on insulins increased by €8.64 and on non-insulins by €13.73. For insulins, holding other factors constant, change in the number of purchases represented a €4.67 increase in expenditure, change in the size of purchases a €4.33 increase and switches between therapeutic classes a €4.07 increase. For non-insulins, change in the number of purchases represented a €10.22 increase in expenditure and switches between therapeutic classes, a €10.17 increase. Changes in purchase size increased the non-insulin per capita expenditure by €1.48. For both insulins and non-insulins, changes in prices and product level switches had decreasing effects on expenditures. CONCLUSIONS: The main drivers of the growth in diabetes drug expenditure were volume growth and switches to newer and more expensive drugs. Price changes, however, had a decreasing effect on the overall diabetes drug expenditure.